Biogen Says BLA For Lecanemab Gets Priority Review By NMPA In China
28/2 08:39
(RTTNews) - Eisai Co., Ltd. and Biogen Inc. (BIIB) Tuesday said the Biologics License Application (BLA) for lecanemab, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China....